Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025European PsychiatryOpen Access

Examine the effects of Atomoxtine alone versus Atomoxtine combined with Risperidone at sample of Egyptian children suffering from ADHD

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMohammed Mahmoud Abdalrahman Hamouda

Discussion

Loading...

Member takes

Overview

Follow-up study on atomoxetine and risperidone efficacy in ADHD children shows combined treatment impacts hyperactivity more.

Key Points

  • Atomoxetine alone showed a moderate efficacy in treating ADHD, with 44.4% of children responding positively.
  • The combination of atomoxetine and risperidone was effective in 88.9% of children, indicating a stronger overall response.
  • Conducted in a clinical setting over six months, the study monitored treatment effects on ADHD symptoms.
  • Results suggest atomoxetine is more beneficial for inattention, while risperidone aids hyperactivity management.

Cite This Study

Mohammed Mahmoud Abdalrahman Hamouda (2025) studied this question.

synapsesocial.com/papers/68d454cb31b076d99fa5a440https://doi.org/10.1192/j.eurpsy.2025.2077
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Analysis of the Efficacy of Atomoxetine Hydrochloride Combined with Psycho-Behavioral Modification Therapy in the Treatment of ADHD in Children2024
  2. 2Efficacy of Oral Methylphenidate and Risperidone in Treatment of Attention-Deficit Hyperactivity Disorder: A Randomized Controlled Trial2024
  3. 3A Systematic Review of the Comparative Efficacy and Safety of Atomoxetine and Methylphenidate in the Treatment of Adults with ADHD2025
  4. 4The promoting effects of digital targeted cognitive training in medication treatment for children with ADHD: A randomized controlled trial2024
  5. 5Effectiveness of Atomoxetine Augmentation in Reducing Nonsuicidal Self-Injury Among Adolescents with Attention Problems: A Preliminary Study.2025